1,260 results on '"Robb, Merlin L."'
Search Results
2. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
- Author
-
Happe, Myra, Hofstetter, Amelia R., Wang, Jing, Yamshchikov, Galina V., Holman, LaSonji A., Novik, Laura, Strom, Larisa, Kiweewa, Francis, Wakabi, Salim, Millard, Monica, Kelley, Colleen F., Kabbani, Sarah, Edupuganti, Srilatha, Beck, Allison, Kaltovich, Florence, Murray, Tamar, Tsukerman, Susanna, Carr, Derick, Ashman, Carl, Stanley, Daphne A., Ploquin, Aurélie, Bailer, Robert T., Schwartz, Richard, Cham, Fatim, Tindikahwa, Allan, Hu, Zonghui, Gordon, Ingelise J., Rouphael, Nadine, Houser, Katherine V., Coates, Emily E., Graham, Barney S., Koup, Richard A., Mascola, John R., Sullivan, Nancy J., Robb, Merlin L., Ake, Julie A., Lyke, Kirsten E., Mulligan, Mark J., Ledgerwood, Julie E., and Kibuuka, Hannah
- Published
- 2024
- Full Text
- View/download PDF
3. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
- Author
-
Mdluli, Thembi, Slike, Bonnie M., Curtis, Daniel J., Shubin, Zhanna, Tran, Ursula, Li, Yifan, Dussupt, Vincent, Mendez-Rivera, Letzibeth, Pinyakorn, Suteeraporn, Stieh, Daniel J., Tomaka, Frank L., Schuitemaker, Hanneke, Pau, Maria G., Colby, Donn J., Kroon, Eugène, Sacdalan, Carlo, de Souza, Mark, Phanupak, Nittaya, Hsu, Denise C., Ananworanich, Jintanat, Ake, Julie A., Trautmann, Lydie, Vasan, Sandhya, Robb, Merlin L., Krebs, Shelly J., Paquin-Proulx, Dominic, and Rolland, Morgane
- Published
- 2024
- Full Text
- View/download PDF
4. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
- Author
-
Gebrehana, Beza, Greenleaf, Melissa E, Hamer, Melinda J, Jansen, Nathan K, Jing, Xiaotang, Kagai, Jael, Kourbanova, Kamila, Koren, Michael A, Martin, Monica L, Wuertz, Kathryn McGuckin, Regules, Jason A, Sanborn, Aaron D, Wallace, David, Zhu, Lei, Gromowski, Gregory D, Corbitt, Courtney, Darden, Janice M, Dussupt, Vincent, Golub, Emily S, Headley, Jarrett A, Jarral, Umair M, King, Jocelyn, Krebs, Shelly J, Lay, Jenny, Lilly, Regina, Lynch, Jennifer, Martinez, Elizabeth J, Mayer, Sandra V, McGeehon, Samantha, Lee, Hyunna, Schech, Steven, Tadesse, Mekdi, Thomas, Paul V, Romem, Yahel, Zografos, Erifile, Lin, Bob C, Narpala, Sandeep R, Wang, Lingshu, Doria-Rose, Nicole A, Carroll, Robin E, Eaton, Amanda, Badraslioglu, Emily D, Koontz, Jason M, Nwaeze, Ugo E, Dawson, Peter, Noll, Alexander J, Orndahl, Christine M, Bray, Amy, Carrion, Ricardo, Jr., Patterson, Jean, Kulkarni, Viraj, Hallam, Cory, Gonzalez, Olga, Gazi, Michal, Ober Shepherd, Brittany L, Scott, Paul T, Hutter, Jack N, Lee, Christine, McCauley, Melanie D, Guzman, Ivelese, Bryant, Christopher, McGuire, Sarah, Kennedy, Jessie, Chen, Wei-Hung, Hajduczki, Agnes, Mdluli, Thembi, Valencia-Ruiz, Anais, Amare, Mihret F, Matyas, Gary R, Rao, Mangala, Rolland, Morgane, Mascola, John R, De Rosa, Stephen C, McElrath, M Juliana, Montefiori, David C, Serebryannyy, Leonid, McDermott, Adrian B, Peel, Sheila A, Collins, Natalie D, Joyce, M Gordon, Robb, Merlin L, Michael, Nelson L, Vasan, Sandhya, and Modjarrad, Kayvon
- Published
- 2024
- Full Text
- View/download PDF
5. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
- Author
-
Benkeser, David, Fong, Youyi, Janes, Holly E., Kelly, Elizabeth J., Hirsch, Ian, Sproule, Stephanie, Stanley, Ann Marie, Maaske, Jill, Villafana, Tonya, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Ayala, Victor, Petropoulos, Christos J., Leith, Andrew, Haugaard, Deanne, Webb, Bill, Lu, Yiwen, Yu, Chenchen, Borate, Bhavesh, van der Laan, Lars W. P., Hejazi, Nima S., Carpp, Lindsay N., Randhawa, April K., Andrasik, Michele P., Kublin, James G., Isaacs, Margaret Brewinski, Makhene, Mamodikoe, Tong, Tina, Robb, Merlin L., Corey, Lawrence, Neuzil, Kathleen M., Follmann, Dean, Hoffman, Corey, Falsey, Ann R., Sobieszczyk, Magdalena, Koup, Richard A., Donis, Ruben O., and Gilbert, Peter B.
- Published
- 2023
- Full Text
- View/download PDF
6. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
- Author
-
Falsey, Ann R, Sobieszczyk, Magdalena E, Hirsch, Ian, Sproule, Stephanie, Robb, Merlin L, Corey, Lawrence, Neuzil, Kathleen M, Hahn, William, Hunt, Julie, Mulligan, Mark J, McEvoy, Charlene, DeJesus, Edwin, Hassman, Michael, Little, Susan J, Pahud, Barbara A, Durbin, Anna, Pickrell, Paul, Daar, Eric S, Bush, Larry, Solis, Joel, Carr, Quito Osuna, Oyedele, Temitope, Buchbinder, Susan, Cowden, Jessica, Vargas, Sergio L, Guerreros Benavides, Alfredo, Call, Robert, Keefer, Michael C, Kirkpatrick, Beth D, Pullman, John, Tong, Tina, Brewinski Isaacs, Margaret, Benkeser, David, Janes, Holly E, Nason, Martha C, Green, Justin A, Kelly, Elizabeth J, Maaske, Jill, Mueller, Nancy, Shoemaker, Kathryn, Takas, Therese, Marshall, Richard P, Pangalos, Menelas N, Villafana, Tonya, and Gonzalez-Lopez, Antonio
- Subjects
Clinical Trials and Supportive Activities ,Lung ,Patient Safety ,Vaccine Related ,Prevention ,Immunization ,Clinical Research ,Infectious Diseases ,Emerging Infectious Diseases ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antibodies ,Neutralizing ,Antibodies ,Viral ,COVID-19 ,ChAdOx1 nCoV-19 ,Chile ,Double-Blind Method ,Female ,Humans ,Immunogenicity ,Vaccine ,Male ,Middle Aged ,Peru ,SARS-CoV-2 ,Spike Glycoprotein ,Coronavirus ,United States ,Vaccine Efficacy ,Young Adult ,AstraZeneca AZD1222 Clinical Study Group ,Medical and Health Sciences ,General & Internal Medicine - Abstract
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru.ResultsA total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P
- Published
- 2021
7. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study
- Author
-
Marichannegowda, Manukumar Honnayakanahalli, Zemil, Michelle, Wieczorek, Lindsay, Sanders-Buell, Eric, Bose, Meera, O'Sullivan, Anne Marie, King, David, Francisco, Leilani, Diaz-Mendez, Felisa, Setua, Saini, Chomont, Nicolas, Phanuphak, Nittaya, Ananworanich, Jintanat, Hsu, Denise, Vasan, Sandhya, Michael, Nelson L., Eller, Leigh Anne, Tovanabutra, Sodsai, Tagaya, Yutaka, Robb, Merlin L., Polonis, Victoria R., and Song, Hongshuo
- Published
- 2023
- Full Text
- View/download PDF
8. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
- Author
-
Abalos, Karina, Accini, Jose, Aloysia, Naveena, Amuasi, John Humphrey, Ansah, Nana Akosua, Benkeser, David, Berge, Aude, Beyko, Hanna, Bilotkach, Oleksandra, Breuer, Thomas, Bonfanti, Alberto Cadena, Bukusi, Elisabeth, Canter, Richard, Carrillo, Jaime Augusto, Chansinghakul, Danaya, Coux, Florence, Das, Chandan, Das, Santa Kumar, Devlin, Louis, Espinoza, Luis, Fay, Michael, Follmann, Dean, Frago, Carina, Garinga, Agnes, Gilbert, Peter B, Gonzalez, Claudia, Granados, Maria Angelica, Guillery, Lea, Huang, Ying, Hudzina, Kathy, Jain, Manish, Kanodia, Piush, Khandelwal, Nitin, Mutuluuza, Cissy Kityo, Kiweewa, Francis, Kiwanuka, Noah, Kosolsak, Chalit, Kukian, Darshna, Kushwaha, Jitendra Singh, Laot, Thelma, Lopez-Medina, Eduardo, Macareno Arroyo, Hugo, Mandaliya, Kishorchandra, Mamod, Stephanie, Mangarule, Somnath, Martínez, Javier, McClelland, Scott, Menard, Lisa, Mendoza, Sandra, Mohapatra, Satyajit, Moreau, Catherine, Mugo, Nelly, Nduba, Videlis, Noriega, Fernando, Ntege, Patricia Nahirya, Okech, Brenda, Otero, Maria, Ouma, Samuel Gurrion, Oyieko, Janet, Paredes, Mercedes, Pardo, Erwin, Postol, Svitlana, Pekala, David, Peng, Penny, Py, Marie-Laure, Rivas, Enrique, Rivero, Rafael, Rodriguez, Edith, Saleh, Mansoor, Sánchez, Pedro, Sater, Nessryne, Shah, Jinen, Shrestha, Rajeev, Siika, Abraham, Singh, Chandramani, Singh, Veer Bahadur, Tamrakar, Dipesh, Tavares Da-Silva, Fernanda, Otieno Tina, Lucas, Velasquez, Hector, Wabwire, Deo, Wajja, Anne, Zaworski, Elodie, Zhang, Nianxian, Dayan, Gustavo H, Rouphael, Nadine, Walsh, Stephen R, Chen, Aiying, Grunenberg, Nicole, Allen, Mary, Antony, Johannes, Asante, Kwaku Poku, Bhate, Amit Suresh, Beresnev, Tatiana, Bonaparte, Matthew I, Celle, Médéric, Ceregido, Maria Angeles, Corey, Lawrence, Dobrianskyi, Dmytro, Fu, Bo, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Juraska, Michal, Kee, Jia Jin, Kibuuka, Hannah, Koutsoukos, Marguerite, Masotti, Roger, Michael, Nelson L, Neuzil, Kathleen M, Reynales, Humberto, Robb, Merlin L, Villagómez Martínez, Sandra M, Sawe, Fredrick, Schuerman, Lode, Tong, Tina, Treanor, John, Wartel, T Anh, Diazgranados, Carlos A, Chicz, Roman M, Gurunathan, Sanjay, Savarino, Stephen, and Sridhar, Saranya
- Published
- 2023
- Full Text
- View/download PDF
9. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
- Author
-
Abalos, Karina, Adams, Michael, Allaw, Mohamed, Aloysia, Naveena, Amuasi, John Humphrey, Ansah, Nana Akosua, Asante, Kwaku Poku, Benkeser, David, Berge, Aude, Breuer, Thomas, Briesemeister, Liz, Broder, Gail, Bonfanti, Alberto Cadena, Calinescu, Cornell, Canter, Richard, Carrillo, Jaime Augusto, Chansinghakul, Danaya, Coux, Florence, Das, Chandan, Davies, Matthew, Devlin, Louis, Fay, Michael, Follmann, Dean, Frago, Carina, Fukase, Hiroyuki, Garinga, Agnes, Gilbert, Peter B., Gonzalez, Claudia, Granados, Maria Angelica, Greiwe, Cathy, Guillery, Lea, Hall, Jessicalee, Henderson, Jeffrey, Huang, Ying, Hudzina, Kathy, Hural, John, Hutchens, Mark, Jain, Manish, Jennings, William, Kanodia, Piush, Kimmel, Murray, Kirby, William, Khandelwal, Nitin, Kopp, James, Kosolsak, Chalit, Kublin, Jim, Kukian, Darshna, Kushwaha, Jitendra Singh, Laot, Thelma, Lopez-Medina, Eduardo, Arroyo, Hugo Macareno, Mamod, Stephanie, Mangarule, Somnath, Martin, Troy, Menard, Lisa, Mendoza, Sandra, Meyer, Robert, Middleton, Randle, Miracle, Jill, Mizuyama, Kazuyuki, Mohapatra, Satyajit, Moreau, Catherine, Murray, Linda, Nagamatsu, Shinya, Newberg, Joseph, Noriega, Fernando, Nugent, Paul, Peake-Andrasik, Michele, Pekala, David, Peng, Penny, Py, Marie-Laure, Ramirez, Shelly, Reddy, Chinthaparthi Prabhakar, Reynolds, Michelle, Rivas, Enrique, Sater, Nessryne, Shah, Jinen, Sher, Lawrence, Sieger, Silva, Singh, Chandramani, Singh, Veer Bahadur, Sirisuphmitr, Nuchra, Starkey, Thomas, Suzuki, Kazuo, Tamrakar, Dipesh, Tangemen, Cayce, Da-Silva, Fernanda Tavares, Taylor, David, Tharenos, Leslie, Wartel, T. Anh, Zaworski, Elodie, Zhang, Nianxian, Dayan, Gustavo H., Rouphael, Nadine, Walsh, Stephen R., Chen, Aiying, Grunenberg, Nicole, Allen, Mary, Antony, Johannes, Bhate, Amit Suresh, Beresnev, Tatiana, Bonaparte, Matthew I., Celle, Médéric, Ceregido, Maria Angeles, Corey, Lawrence, Fu, Bo, Grillet, Marie-Helene, Keshtkar-Jahromi, Maryam, Juraska, Michal, Kee, Jia Jin, Kaali, Seyram, Koutsoukos, Marguerite, Masotti, Roger, Michael, Nelson L., Neuzil, Kathleen M., Reynales, Humberto, Robb, Merlin L., Uchiyama, Akiyoshi, Sawe, Fredrick, Schuerman, Lode, Shrestha, Rajeev, Tong, Tina, Treanor, John, Diazgranados, Carlos A., Chicz, Roman M., Gurunathan, Sanjay, Savarino, Stephen, and Sridhar, Saranya
- Published
- 2023
- Full Text
- View/download PDF
10. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
- Author
-
Koren, Michael A, Lin, Leyi, Eckels, Kenneth H, De La Barrera, Rafael, Dussupt, Vincent, Donofrio, Gina, Sondergaard, Erica L, Mills, Kristin T, Robb, Merlin L, Lee, Christine, Adedeji, Oluwaseun, Keiser, Paul B, Curley, Justin M, Copeland, Nathanial K, Crowell, Trevor A, Hutter, Jack N, Hamer, Melinda J, Valencia-Ruiz, Anais, Darden, Janice, Peel, Sheila, Amare, Mihret F, Mebrahtu, Tsedal, Costanzo, Margaret, Krebs, Shelly J, Gromowski, Gregory D, Jarman, Richard G, Thomas, Stephen J, Michael, Nelson L, and Modjarrad, Kayvon
- Published
- 2023
- Full Text
- View/download PDF
11. Initial productive and latent HIV infections originate in vivo by infection of resting T cells
- Author
-
Wietgrefe, Stephen W., Anderson, Jodi, Duan, Lijie, Southern, Peter J., Zuck, Paul, Wu, Guoxin, Howell, Bonnie J., Reilly, Cavan, Kroon, Eugene, Chottanapund, Suthat, Buranapraditkun, Supranee, Sacdalan, Carlo, Tulmethakaan, Nicha, Colby, Donn J., Chomchey, Nitiya, Prueksakaew, Peeriya, Pinyakorn, Suteeraporn, Trichavaroj, Rapee, Mitchell, Julie L., Trautmann, Lydie, Hsu, Denise, Vasan, Sandhya, Manasnayakorn, Sopark, de Souza, Mark, Tovanabutra, Sodsai, Schuetz, Alexandra, Robb, Merlin L., Phanuphak, Nittaya, Ananworanich, Jintanat, Schacker, Timothy W., and Haase, Ashley T.
- Subjects
Merck & Company Inc. ,Thermo Fisher Scientific Inc. ,HIV (Viruses) -- Health aspects ,Scientific equipment and supplies industry -- Health aspects ,T cells -- Health aspects ,Antiviral agents -- Health aspects ,Highly active antiretroviral therapy -- Health aspects ,Pharmaceutical industry -- Health aspects ,HIV infection -- Health aspects ,Health care industry ,University of Minnesota - Abstract
Productively infected cells are generally thought to arise from HIV infection of activated [CD4.sup.+] T cells, and these infected activated cells are thought to be a recurring source of latently infected cells when a portion of the population transitions to a resting state. We discovered and report here that productively and latently infected cells can instead originate from direct infection of resting [CD4.sup.+] T cell populations in lymphoid tissues in Fiebig I, the earliest stage of detectable HIV infection. We found that direct infection of resting [CD4.sup.+] T cells was correlated with the availability of susceptible target cells in lymphoid tissues largely restricted to resting [CD4.sup.+] T cells in which expression of pTEFb enabled productive infection, and we documented persistence of HIV-producing resting T cells during antiretroviral therapy (ART). Thus, we provide evidence of a mechanism by which direct infection of resting T cells in lymphoid tissues to generate productively and latently infected cells creates a mechanism by which the productively infected cells can replenish both populations and maintain two sources of virus from which HIV infection can rebound, even if ART is instituted at the earliest stage of detectable infection., Introduction From the beginning of HIV research, HIV has been mainly propagated in vitro in tissue cultures of activated [CD4.sup.+] T cells (1), leading to the prevailing view that activated [...]
- Published
- 2023
- Full Text
- View/download PDF
12. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes
- Author
-
Sankhala, Rajeshwer S., Dussupt, Vincent, Donofrio, Gina, Gromowski, Gregory D., De La Barrera, Rafael A., Larocca, Rafael A., Mendez-Rivera, Letzibeth, Lee, Anna, Choe, Misook, Zaky, Weam, Mantus, Grace, Jensen, Jaime L., Chen, Wei-Hung, Gohain, Neelakshi, Bai, Hongjun, McCracken, Michael K., Mason, Rosemarie D., Leggat, David, Slike, Bonnie M., Tran, Ursula, Jian, Ningbo, Abbink, Peter, Peterson, Rebecca, Mendes, Erica Araujo, Freitas de Oliveira Franca, Rafael, Calvet, Guilherme Amaral, Bispo de Filippis, Ana Maria, McDermott, Adrian, Roederer, Mario, Hernandez, Mayda, Albertus, Amie, Davidson, Edgar, Doranz, Benjamin J., Rolland, Morgane, Robb, Merlin L., Lynch, Rebecca M., Barouch, Dan H., Jarman, Richard G., Thomas, Stephen J., Modjarrad, Kayvon, Michael, Nelson L., Krebs, Shelly J., and Joyce, M. Gordon
- Published
- 2023
- Full Text
- View/download PDF
13. Preparing for future European efficacy trials of interventions to prevent HIV and other sexually transmitted infections: Lessons on willingness to participate and barriers to participation from ten German clinics serving behaviorally vulnerable men who have sex with men
- Author
-
Esber, Allahna L., Jansen, Klaus, Dorsey-Spitz, Julie, Robb, Merlin L., Streeck, Hendrik, and Crowell, Trevor A.
- Published
- 2023
- Full Text
- View/download PDF
14. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.
- Author
-
Lal, Kerri G, Kim, Dohoon, Costanzo, Margaret C, Creegan, Matthew, Leeansyah, Edwin, Dias, Joana, Paquin-Proulx, Dominic, Eller, Leigh Anne, Schuetz, Alexandra, Phuang-Ngern, Yuwadee, Krebs, Shelly J, Slike, Bonnie M, Kibuuka, Hannah, Maganga, Lucas, Nitayaphan, Sorachai, Kosgei, Josphat, Sacdalan, Carlo, Ananworanich, Jintanat, Bolton, Diane L, Michael, Nelson L, Shacklett, Barbara L, Robb, Merlin L, Eller, Michael A, and Sandberg, Johan K
- Abstract
Mucosa-associated invariant T (MAIT) cell loss in chronic HIV-1 infection is a significant insult to antimicrobial immune defenses. Here we investigate the response of MAIT cells during acute HIV-1 infection utilizing the RV217 cohort with paired longitudinal pre- and post-infection samples. MAIT cells are activated and expand in blood and mucosa coincident with peak HIV-1 viremia, in a manner associated with emerging microbial translocation. This is followed by a phase with elevated function as viral replication is controlled to a set-point level, and later by their functional decline at the onset of chronic infection. Interestingly, enhanced innate-like pathways and characteristics develop progressively in MAIT cells during infection, in parallel with TCR repertoire alterations. These findings delineate the dynamic MAIT cell response to acute HIV-1 infection, and show how the MAIT compartment initially responds and expands with enhanced function, followed by progressive reprogramming away from TCR-dependent antibacterial responses towards innate-like functionality.
- Published
- 2020
15. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection
- Author
-
Peluso, Michael J, Colby, Donn J, Pinyakorn, Suteeraporn, Ubolyam, Sasiwimol, Intasan, Jintana, Trichavaroj, Rapee, Chomchey, Nitiya, Prueksakaew, Peeriya, Slike, Bonnie M, Krebs, Shelly J, Jian, Ningbo, Robb, Merlin L, Phanuphak, Praphan, Phanuphak, Nittaya, Spudich, Serena, Ananworanich, Jintanat, Kroon, Eugène, Teeratakulpisarn, Nipat, Pattanachaiwit, Supanit, Sacdalan, Carlo, Sriplienchan, Somchai, de Souza, Mark, Tantivitayakul, Ponpen, Poltavee, Kultida, Luekasemsuk, Tassanee, Savadsuk, Hathairat, Tipsuk, Somporn, Puttamsawin, Suwanna, Benjapornpong, Khunthalee, Ratnaratorn, Nisakorn, Tangnaree, Kamonkan, Munkong, Chutharat, Thaimanee, Rommanus, Eamyoung, Patcharin, Buranapraditkun, Supranee, Lerdlum, Sukalya, Manasnayakorn, Sopark, Rerknimitr, Rugsun, Sirivichayakul, Sunee, Wattanaboonyongcharoen, Phandee, Suttichom, Duanghathai, O'Connell, Robert, Schuetz, Alexandra, Hsu, Denise, Akapirat, Siriwat, Nuntapinit, Bessara, Tantibul, Nantana, Churikanont, Nampueng, Getchalarat, Saowanit, Michael, Nelson, Vasan, Sandhya, Crowell, Trevor, Turk, Ellen, McCullough, Corinne, Butterworth, Oratai, Milazzo, Mark, and Anne Eller, Leigh
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Digestive Diseases ,Clinical Research ,Infectious Diseases ,Liver Disease ,HIV/AIDS ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Aetiology ,2.1 Biological and endogenous factors ,Infection ,Good Health and Well Being ,Adult ,Alanine Transaminase ,Alkynes ,Benzoxazines ,Cohort Studies ,Cyclopropanes ,Female ,HIV Infections ,Humans ,Liver Diseases ,Liver Function Tests ,Male ,Thailand ,Young Adult ,HIV ,acute HIV ,liver function tests ,Acquired Immunodeficiency Syndrome ,antiretroviral agents ,anti-HIV agents ,SEARCH010/RV254 Study Group ,Public Health and Health Services ,Other Medical and Health Sciences ,Clinical sciences ,Epidemiology ,Public health - Abstract
IntroductionLiver disease is a common cause of non-AIDS morbidity and mortality in people living with HIV (PLHIV), but the prevalence and significance of liver function test (LFT) abnormalities in early HIV infection is unknown. This study aimed to characterize LFTs in a large cohort of participants with acute HIV infection initiating immediate antiretroviral therapy (ART) and examine the association between LFTs and biomarkers of HIV infection and inflammation.MethodsWe measured LFTs at the time of HIV diagnosis and at 4, 12, 24 and 48 weeks after ART initiation in 426 Thai individuals with acute HIV infection from 2009 to 2018. A subset of individuals had data available at 96 and 144 weeks. We excluded individuals with concomitant viral hepatitis. Alanine aminotransferase (ALT) was the primary outcome of interest; values greater than 1.25 times the upper limit of normal were considered elevated. Analyses utilized descriptive statistics, non-parametric tests and multivariate logistic regression.ResultsSixty-six of the 426 individuals (15.5%) had abnormal baseline ALT levels; the majority (43/66, 65.5%) had Grade 1 elevations. Elevated baseline ALT correlated with Fiebig stages III to V (p = 0.001) and baseline HIV RNA >6 log10 copies/mL (p = 0.012). Baseline elevations resolved by 48 weeks on ART in 59 of the 66 individuals (89%). ALT elevations at 24 and 48 weeks correlated with Fiebig stages I to II at diagnosis (p 350 cells/μL (p = 0.03) and older age (p = 0.03). Individuals initiating efavirenz-based regimens were more likely to have elevated ALT levels at 48 weeks compared with those on non-efavirenz-based regimens (p = 0.003).ConclusionsOne in six people with acute HIV infection have elevated LFTs. Clinical outcomes with ART started in acute HIV are generally good, with resolution of ALT elevations within 48 weeks on ART in most cases. These results suggest a multifactorial model for hepatic injury involving a combination of HIV-associated and ART-associated processes, which may change over time.
- Published
- 2020
16. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa
- Author
-
RV217, RV254/SEARCH010, RV304/SEARCH013 StudyGroup, Paquin-Proulx, Dominic, Lal, Kerri G., Phuang-Ngern, Yuwadee, Creegan, Matthew, Tokarev, Andrey, Suhkumvittay, Suchada, Alrubayyi, Aljawharah, Kroon, Eugène, Pinyakorn, Suteeraporn, Slike, Bonnie M., Bolton, Diane L., Krebs, Shelly J., Eller, Leigh Anne, Sajjaweerawan, Chayada, Pagliuzza, Amélie, Chomont, Nicolas, Rerknimitr, Rungsun, Chomchey, Nitiya, Phanuphak, Nittaya, de Souza, Mark S., Michael, Nelson L., Robb, Merlin L., Ananworanich, Jintanat, Sandberg, Johan K., Eller, Michael A., and Schuetz, Alexandra
- Published
- 2021
17. HIV rapidly targets a diverse pool of CD4+ T cells to establish productive and latent infections
- Author
-
Gantner, Pierre, Buranapraditkun, Supranee, Pagliuzza, Amélie, Dufour, Caroline, Pardons, Marion, Mitchell, Julie L., Kroon, Eugène, Sacdalan, Carlo, Tulmethakaan, Nicha, Pinyakorn, Suteeraporn, Robb, Merlin L., Phanuphak, Nittaya, Ananworanich, Jintanat, Hsu, Denise, Vasan, Sandhya, Trautmann, Lydie, Fromentin, Rémi, and Chomont, Nicolas
- Published
- 2023
- Full Text
- View/download PDF
18. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
- Author
-
Lampley, Rebecca, Larkin, Brenda, Costner, Pamela, Wilson, Hope, Read, Mike, Hamer, Melinda J, Houser, Katherine V, Hofstetter, Amelia R, Ortega-Villa, Ana M, Lee, Christine, Preston, Anne, Augustine, Brooke, Andrews, Charla, Yamshchikov, Galina V, Hickman, Somia, Schech, Steven, Hutter, Jack N, Scott, Paul T, Waterman, Paige E, Amare, Mihret F, Kioko, Victoria, Storme, Casey, Modjarrad, Kayvon, McCauley, Melanie D, Robb, Merlin L, Gaudinski, Martin R, Gordon, Ingelise J, Holman, LaSonji A, Widge, Alicia T, Strom, Larisa, Happe, Myra, Cox, Josephine H, Vazquez, Sandra, Stanley, Daphne A, Murray, Tamar, Dulan, Caitlyn N M, Hunegnaw, Ruth, Narpala, Sandeep R, Swanson, Phillip A, II, Basappa, Manjula, Thillainathan, Jagada, Padilla, Marcelino, Flach, Britta, O’Connell, Sarah, Trofymenko, Olga, Morgan, Patricia, Coates, Emily E, Gall, Jason G, McDermott, Adrian B, Koup, Richard A, Mascola, John R, Ploquin, Aurélie, Sullivan, Nancy J, Ake, Julie A, and Ledgerwood, Julie E
- Published
- 2023
- Full Text
- View/download PDF
19. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
- Author
-
Ober Shepherd, Brittany L, primary, Scott, Paul T, additional, Hutter, Jack N, additional, Lee, Christine, additional, McCauley, Melanie D, additional, Guzman, Ivelese, additional, Bryant, Christopher, additional, McGuire, Sarah, additional, Kennedy, Jessie, additional, Chen, Wei-Hung, additional, Hajduczki, Agnes, additional, Mdluli, Thembi, additional, Valencia-Ruiz, Anais, additional, Amare, Mihret F, additional, Matyas, Gary R, additional, Rao, Mangala, additional, Rolland, Morgane, additional, Mascola, John R, additional, De Rosa, Stephen C, additional, McElrath, M Juliana, additional, Montefiori, David C, additional, Serebryannyy, Leonid, additional, McDermott, Adrian B, additional, Peel, Sheila A, additional, Collins, Natalie D, additional, Joyce, M Gordon, additional, Robb, Merlin L, additional, Michael, Nelson L, additional, Vasan, Sandhya, additional, Modjarrad, Kayvon, additional, Gebrehana, Beza, additional, Greenleaf, Melissa E, additional, Hamer, Melinda J, additional, Jansen, Nathan K, additional, Jing, Xiaotang, additional, Kagai, Jael, additional, Kourbanova, Kamila, additional, Koren, Michael A, additional, Martin, Monica L, additional, Wuertz, Kathryn McGuckin, additional, Regules, Jason A, additional, Sanborn, Aaron D, additional, Wallace, David, additional, Zhu, Lei, additional, Gromowski, Gregory D, additional, Corbitt, Courtney, additional, Darden, Janice M, additional, Dussupt, Vincent, additional, Golub, Emily S, additional, Headley, Jarrett A, additional, Jarral, Umair M, additional, King, Jocelyn, additional, Krebs, Shelly J, additional, Lay, Jenny, additional, Lilly, Regina, additional, Lynch, Jennifer, additional, Martinez, Elizabeth J, additional, Mayer, Sandra V, additional, McGeehon, Samantha, additional, Lee, Hyunna, additional, Schech, Steven, additional, Tadesse, Mekdi, additional, Thomas, Paul V, additional, Romem, Yahel, additional, Zografos, Erifile, additional, Lin, Bob C, additional, Narpala, Sandeep R, additional, Wang, Lingshu, additional, Doria-Rose, Nicole A, additional, Carroll, Robin E, additional, Eaton, Amanda, additional, Badraslioglu, Emily D, additional, Koontz, Jason M, additional, Nwaeze, Ugo E, additional, Dawson, Peter, additional, Noll, Alexander J, additional, Orndahl, Christine M, additional, Bray, Amy, additional, Carrion, Ricardo, additional, Patterson, Jean, additional, Kulkarni, Viraj, additional, Hallam, Cory, additional, Gonzalez, Olga, additional, and Gazi, Michal, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Author response: A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1
- Author
-
Rao, Venigalla B, primary, Jain, Swati, additional, Uritskiy, Gherman, additional, Mahalingam, Marthandan, additional, Batra, Himanshu, additional, Chand, Subhash, additional, Trinh, Hung V, additional, Beck, Charles, additional, Shin, Woong-Hee, additional, Alsalmi, Wadad, additional, Kijak, Gustavo, additional, Eller, Leigh A, additional, Kim, Jerome, additional, Kihara, Daisuke, additional, Tovanabutra, Sodsai, additional, Ferrari, Guido, additional, Robb, Merlin L, additional, and Rao, Mangala, additional
- Published
- 2024
- Full Text
- View/download PDF
21. A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1
- Author
-
Jain, Swati, primary, Uritskiy, Gherman, additional, Mahalingam, Marthandan, additional, Batra, Himanshu, additional, Chand, Subhash, additional, Trinh, Hung V, additional, Beck, Charles, additional, Shin, Woong-Hee, additional, Alsalmi, Wadad, additional, Kijak, Gustavo, additional, Eller, Leigh A, additional, Kim, Jerome, additional, Kihara, Daisuke, additional, Tovanabutra, Sodsai, additional, Ferrari, Guido, additional, Robb, Merlin L, additional, Rao, Mangala, additional, and Rao, Venigalla B, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
- Author
-
Julg, Boris, Dee, Lynda, Ananworanich, Jintanat, Barouch, Dan H, Bar, Katharine, Caskey, Marina, Colby, Donn J, Dawson, Liza, Dong, Krista L, Dubé, Karine, Eron, Joseph, Frater, John, Gandhi, Rajesh T, Geleziunas, Romas, Goulder, Philip, Hanna, George J, Jefferys, Richard, Johnston, Rowena, Kuritzkes, Daniel, Li, Jonathan Z, Likhitwonnawut, Udom, van Lunzen, Jan, Martinez-Picado, Javier, Miller, Veronica, Montaner, Luis J, Nixon, Douglas F, Palm, David, Pantaleo, Giuseppe, Peay, Holly, Persaud, Deborah, Salzwedel, Jessica, Salzwedel, Karl, Schacker, Timothy, Sheikh, Virginia, Søgaard, Ole S, Spudich, Serena, Stephenson, Kathryn, Sugarman, Jeremy, Taylor, Jeff, Tebas, Pablo, Tiemessen, Caroline T, Tressler, Randall, Weiss, Carol D, Zheng, Lu, Robb, Merlin L, Michael, Nelson L, Mellors, John W, Deeks, Steven G, and Walker, Bruce D
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,HIV/AIDS ,Sexually Transmitted Infections ,Infectious Diseases ,Clinical Research ,Clinical Trials and Supportive Activities ,Infection ,Anti-Retroviral Agents ,HIV Infections ,Humans ,Sustained Virologic Response ,Viral Load ,Withholding Treatment ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. In this Review, we present the major points of discussion and consensus views achieved with the goal of informing the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV research.
- Published
- 2019
23. Acute HIV-1 infection viremia associate with rebound upon treatment interruption
- Author
-
Mdluli, Thembi, Li, Yifan, Pinyakorn, Suteeraporn, Reeves, Daniel B., Cardozo-Ojeda, E. Fabian, Yates, Adam, Intasan, Jintana, Tipsuk, Somporn, Phanuphak, Nittaya, Sacdalan, Carlo, Colby, Donn J., Kroon, Eugène, Crowell, Trevor A., Thomas, Rasmi, Robb, Merlin L., Ananworanich, Jintanat, de Souza, Mark, Phanuphak, Praphan, Stieh, Daniel J., Tomaka, Frank L., Trautmann, Lydie, Ake, Julie A., Hsu, Denise C., Francisco, Leilani V., Vasan, Sandhya, and Rolland, Morgane
- Published
- 2022
- Full Text
- View/download PDF
24. Dissecting drivers of immune activation in chronic HIV-1 infection
- Author
-
Streeck, Hendrik, Maestri, Alvino, Habermann, Daniel, Crowell, Trevor A., Esber, Allahna L., Son, Gowoon, Eller, Leigh Anne, Eller, Michael A., Parikh, Ajay P., Horn, Peter A., Maganga, Lucas, Bahemana, Emmanuel, Adamu, Yakubu, Kiweewa, Francis, Maswai, Jonah, Owuoth, John, Robb, Merlin L., Michael, Nelson L., Polyak, Christina S., Hoffmann, Daniel, and Ake, Julie A.
- Published
- 2022
- Full Text
- View/download PDF
25. Brain volumetrics differ by Fiebig stage in acute HIV infection
- Author
-
Bolzenius, Jacob, Sacdalan, Carlo, Ndhlovu, Lishomwa C., Sailasuta, Napapon, Trautmann, Lydie, Tipsuk, Somporn, Crowell, Trevor A., Suttichom, Duanghathai, Colby, Donn J., Phanuphak, Nittaya, Chan, Phillip, Premeaux, Thomas, Kroon, Eugène, Vasan, Sandhya, Hsu, Denise C., Valcour, Victor, Ananworanich, Jintanat, Robb, Merlin L., Ake, Julie A., Pohl, Kilian M., Sriplienchan, Somchai, Spudich, Serena, and Paul, Robert
- Published
- 2023
- Full Text
- View/download PDF
26. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
- Author
-
Ventura, John D., Nkolola, Joseph P., Chandrashekar, Abishek, Borducchi, Erica N., Liu, Jinyan, Mercado, Noe B., Hope, David L., Giffin, Victoria M., McMahan, Katherine, Geleziunas, Romas, Murry, Jeffrey P., Yang, Yunling, Lewis, Mark G., Pau, Maria G., Wegmann, Frank, Schuitemaker, Hanneke, Fray, Emily J., Kumar, Mithra R., Siliciano, Janet D., Siliciano, Robert F., Robb, Merlin L., Michael, Nelson L., and Barouch, Dan H.
- Published
- 2022
- Full Text
- View/download PDF
27. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
- Author
-
Walker-Sperling, Victoria E. K., Mercado, Noe B., Chandrashekar, Abishek, Borducchi, Erica N., Liu, Jinyan, Nkolola, Joseph P., Lewis, Mark, Murry, Jeffrey P., Yang, Yunling, Geleziunas, Romas, Robb, Merlin L., Michael, Nelson L., Pau, Maria G., Wegmann, Frank, Schuitemaker, Hanneke, Fray, Emily J., Kumar, Mithra R., Siliciano, Janet D., Siliciano, Robert F., and Barouch, Dan H.
- Published
- 2022
- Full Text
- View/download PDF
28. Leveraging lessons learned from the COVID-19 pandemic for HIV
- Author
-
Calder, Thomas, Tong, Tina, Hu, Dale J., Kim, Jerome H., Kotloff, Karen L., Koup, Richard A., Marovich, Mary A., McElrath, M. Juliana, Read, Sarah W., Robb, Merlin L., Renzullo, Philip O., and D’Souza, M. Patricia
- Published
- 2022
- Full Text
- View/download PDF
29. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination
- Author
-
Tomalka, Jeffrey Alan, Pelletier, Adam Nicolas, Fourati, Slim, Latif, Muhammad Bilal, Sharma, Ashish, Furr, Kathryn, Carlson, Kevin, Lifton, Michelle, Gonzalez, Ana, Wilkinson, Peter, Franchini, Genoveffa, Parks, Robert, Letvin, Norman, Yates, Nicole, Seaton, Kelly, Tomaras, Georgia, Tartaglia, Jim, Robb, Merlin L., Michael, Nelson L., Koup, Richard, Haynes, Barton, Santra, Sampa, and Sekaly, Rafick Pierre
- Published
- 2021
- Full Text
- View/download PDF
30. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.
- Author
-
Buggert, Marcus, Nguyen, Son, McLane, Laura M, Steblyanko, Maria, Anikeeva, Nadia, Paquin-Proulx, Dominic, Del Rio Estrada, Perla M, Ablanedo-Terrazas, Yuria, Noyan, Kajsa, Reuter, Morgan A, Demers, Korey, Sandberg, Johan K, Eller, Michael A, Streeck, Hendrik, Jansson, Marianne, Nowak, Piotr, Sönnerborg, Anders, Canaday, David H, Naji, Ali, Wherry, E John, Robb, Merlin L, Deeks, Steven G, Reyes-Teran, Gustavo, Sykulev, Yuri, Karlsson, Annika C, and Betts, Michael R
- Subjects
Lymphoid Tissue ,Lymph Nodes ,CD4-Positive T-Lymphocytes ,Humans ,HIV-1 ,HIV Infections ,Viral Load ,Case-Control Studies ,Immunologic Surveillance ,Virology ,Microbiology ,Immunology ,Medical Microbiology - Abstract
CD4+ T cells subsets have a wide range of important helper and regulatory functions in the immune system. Several studies have specifically suggested that circulating effector CD4+ T cells may play a direct role in control of HIV replication through cytolytic activity or autocrine β-chemokine production. However, it remains unclear whether effector CD4+ T cells expressing cytolytic molecules and β-chemokines are present within lymph nodes (LNs), a major site of HIV replication. Here, we report that expression of β-chemokines and cytolytic molecules are enriched within a CD4+ T cell population with high levels of the T-box transcription factors T-bet and eomesodermin (Eomes). This effector population is predominately found in peripheral blood and is limited in LNs regardless of HIV infection or treatment status. As a result, CD4+ T cells generally lack effector functions in LNs, including cytolytic capacity and IFNγ and β-chemokine expression, even in HIV elite controllers and during acute/early HIV infection. While we do find the presence of degranulating CD4+ T cells in LNs, these cells do not bear functional or transcriptional effector T cell properties and are inherently poor to form stable immunological synapses compared to their peripheral blood counterparts. We demonstrate that CD4+ T cell cytolytic function, phenotype, and programming in the peripheral blood is dissociated from those characteristics found in lymphoid tissues. Together, these data challenge our current models based on blood and suggest spatially and temporally dissociated mechanisms of viral control in lymphoid tissues.
- Published
- 2018
31. Computational analysis of antibody dynamics identifies recent HIV-1 infection
- Author
-
Seaton, Kelly E, Vandergrift, Nathan A, Deal, Aaron W, Rountree, Wes, Bainbridge, John, Grebe, Eduard, Anderson, David A, Sawant, Sheetal, Shen, Xiaoying, Yates, Nicole L, Denny, Thomas N, Liao, Hua-Xin, Haynes, Barton F, Robb, Merlin L, Parkin, Neil, Santos, Breno R, Garrett, Nigel, Price, Matthew A, Naniche, Denise, Duerr, Ann C, Keating, Sheila, Hampton, Dylan, Facente, Shelley, Marson, Kara, Welte, Alex, Pilcher, Christopher D, Cohen, Myron S, and Tomaras, Georgia D
- Subjects
HIV/AIDS ,Vaccine Related (AIDS) ,Prevention ,Infectious Diseases ,Pediatric AIDS ,Vaccine Related ,Pediatric ,Immunization ,Infection ,Good Health and Well Being ,Antibody Affinity ,Antigen-Antibody Reactions ,Biomarkers ,Computational Biology ,HIV Antibodies ,HIV Antigens ,HIV Infections ,HIV-1 ,Humans ,Immunoglobulin G ,Incidence ,Retrospective Studies ,Time Factors ,CEPHIA group ,AIDS/HIV ,Antigen ,Immunoglobulins ,Immunology - Abstract
Accurate HIV-1 incidence estimation is critical to the success of HIV-1 prevention strategies. Current assays are limited by high false recent rates (FRRs) in certain populations and a short mean duration of recent infection (MDRI). Dynamic early HIV-1 antibody response kinetics were harnessed to identify biomarkers for improved incidence assays. We conducted retrospective analyses on circulating antibodies from known recent and longstanding infections and evaluated binding and avidity measurements of Env and non-Env antigens and multiple antibody forms (i.e., IgG, IgA, IgG3, IgG4, dIgA, and IgM) in a diverse panel of 164 HIV-1-infected participants (clades A, B, C). Discriminant function analysis identified an optimal set of measurements that were subsequently evaluated in a 324-specimen blinded biomarker validation panel. These biomarkers included clade C gp140 IgG3, transmitted/founder clade C gp140 IgG4 avidity, clade B gp140 IgG4 avidity, and gp41 immunodominant region IgG avidity. MDRI was estimated at 215 day or alternatively, 267 days. FRRs in untreated and treated subjects were 5.0% and 3.6%, respectively. Thus, computational analysis of dynamic HIV-1 antibody isotype and antigen interactions during infection enabled design of a promising HIV-1 recency assay for improved cross-sectional incidence estimation.
- Published
- 2017
32. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection
- Author
-
Teigler, Jeffrey E, Zelinskyy, Gennadiy, Eller, Michael A, Bolton, Diane L, Marovich, Mary, Gordon, Alexander D, Alrubayyi, Aljawharah, Alter, Galit, Robb, Merlin L, Martin, Jeffrey N, Deeks, Steven G, Michael, Nelson L, Dittmer, Ulf, and Streeck, Hendrik
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Infectious Diseases ,Emerging Infectious Diseases ,HIV/AIDS ,Sexually Transmitted Infections ,Immunotherapy ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Infection ,Good Health and Well Being ,Animals ,Antibodies ,CD4-Positive T-Lymphocytes ,CTLA-4 Antigen ,Costimulatory and Inhibitory T-Cell Receptors ,Cytokines ,Enterotoxins ,Friend murine leukemia virus ,Gene Expression ,HIV Infections ,Humans ,Interferon-gamma ,Mice ,Programmed Cell Death 1 Receptor ,Retroviridae Infections ,Tumor Necrosis Factor-alpha ,CD4 T cells ,CTLA-4 ,HIV ,PD-1 ,inhibitory receptors ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Virology ,Agricultural ,veterinary and food sciences ,Biological sciences ,Biomedical and clinical sciences - Abstract
Inhibitory receptors have been extensively described for their importance in regulating immune responses in chronic infections and cancers. Blocking the function of inhibitory receptors such as PD-1, CTLA-4, 2B4, Tim-3, and LAG-3 has shown promise for augmenting CD8 T cell activity and boosting pathogen-specific immunity. However, the prevalence of inhibitory receptors on CD4 T cells and their relative influence on CD4 T cell functionality in chronic HIV infection remains poorly described. We therefore determined and compared inhibitory receptor expression patterns of 2B4, CTLA-4, LAG-3, PD-1, and Tim-3 on virus-specific CD4 and CD8 T cells in relation to their functional T cell profile. In chronic HIV infection, inhibitory receptor distribution differed markedly between cytokine-producing T cell subsets with, gamma interferon (IFN-γ)- and tumor necrosis factor alpha (TNF-α)-producing cells displaying the highest and lowest prevalence of inhibitory receptors, respectively. Blockade of inhibitory receptors differentially affected cytokine production by cells in response to staphylococcal enterotoxin B stimulation. CTLA-4 blockade increased IFN-γ and CD40L production, while PD-1 blockade strongly augmented IFN-γ, interleukin-2 (IL-2), and TNF-α production. In a Friend retrovirus infection model, CTLA-4 blockade in particular was able to improve control of viral replication. Together, these results show that inhibitory receptor distribution on HIV-specific CD4 T cells varies markedly with respect to the functional subset of CD4 T cells being analyzed. Furthermore, the differential effects of receptor blockade suggest novel methods of immune response modulation, which could be important in the context of HIV vaccination or therapeutic strategies.IMPORTANCE Inhibitory receptors are important for limiting damage by the immune system during acute infections. In chronic infections, however, their expression limits immune system responsiveness. Studies have shown that blocking inhibitory receptors augments CD8 T cell functionality in HIV infection, but their influence on CD4 T cells remains unclear. We assessed the expression of inhibitory receptors on HIV-specific CD4 T cells and their relationship with T cell functionality. We uncovered differences in inhibitory receptor expression depending on the CD4 T cell function. We also found differences in functionality of CD4 T cells following blocking of different inhibitory receptors, and we confirmed our results in a Friend virus retroviral model of infection in mice. Our results show that inhibitory receptor expression on CD4 T cells is linked to CD4 T cell functionality and could be sculpted by blockade of specific inhibitory receptors. These data reveal exciting possibilities for the development of novel treatments and immunotherapeutics.
- Published
- 2017
33. Author Response: A Remarkable Genetic Shift in a Transmitted/Founder Virus Broadens Antibody Responses Against HIV-1
- Author
-
Jain, Swati, primary, Uritskiy, Gherman, additional, Mahalingam, Marthandan, additional, Batra, Himanshu, additional, Chand, Subhash, additional, Trinh, Hung V., additional, Beck, Charles, additional, Shin, Woong-Hee, additional, AlSalmi, Wadad, additional, Kijak, Gustavo, additional, Eller, Leigh A., additional, Kim, Jerome, additional, Kihara, Daisuke, additional, Tovanabutra, Sodsai, additional, Ferrari, Guido, additional, Robb, Merlin L., additional, Rao, Mangala, additional, and Rao, Venigalla B., additional
- Published
- 2024
- Full Text
- View/download PDF
34. Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand
- Author
-
Wansom, Tanyaporn, Muangnoicharoen, Sant, Nitayaphan, Sorachai, Kitsiripornchai, Suchai, Crowell, Trevor A., Francisco, Leilani, Gilbert, Paileen, Rwakasyaguri, Dixion, Dhitavat, Jittima, Li, Qun, King, David, Robb, Merlin L., Smith, Kirsten, Heger, Elizabeth A., Akapirat, Siriwat, Pitisuttithum, Punnee, O'Connell, Robert J., and Vasan, Sandhya
- Published
- 2021
- Full Text
- View/download PDF
35. Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults
- Author
-
Cohen, Kristen W., Fiore-Gartland, Andrew, Walsh, Stephen R., Yusim, Karina, Frahm, Nicole, Elizaga, Marnie L., Maenza, Janine, Scott, Hyman, Mayer, Kenneth H., Goepfert, Paul A., Edupuganti, Srilatha, Pantaleo, Giuseppe, Hutter, Julia, Morris, Daryl E., de Rosa, Stephen C., Geraghty, Daniel E., Robb, Merlin L., Michael, Nelson L., Fischer, Will, Giorgi, Elena E., Malhi, Harmandeep, Pensiero, Michael N., Ferrari, Guido, Tomaras, Georgia D., Montefiori, David C., Gilbert, Peter B., McElrath, M. Juliana, Haynes, Barton F., Korber, Bette T., and Baden, Lindsey R.
- Subjects
Cellular immunity -- Health aspects ,Immune response -- Health aspects ,DNA vaccines -- Testing ,Antigens -- Health aspects ,AIDS vaccines -- Testing ,HIV infection -- Drug therapy ,Health care industry - Abstract
BACKGROUND. Mosaic and consensus HIV-1 immunogens provide two distinct approaches to elicit greater breadth of coverage against globally circulating HIV-1 and have shown improved immunologic breadth in nonhuman primate models. METHODS. This double-blind randomized trial enrolled 105 healthy HIV-uninfected adults who received 3 doses of either a trivalent global mosaic, a group M consensus (CON-S), or a natural clade B (Nat-B) gp160 env DNA vaccine followed by 2 doses of a heterologous modified vaccinia Ankara-vectored HIV-1 vaccine or placebo. We performed prespecified blinded immunogenicity analyses at day 70 and day 238 after the first immunization. T cell responses to vaccine antigens and 5 heterologous Env variants were fully mapped. RESULTS. Env-specific [CD4.sup.+] T cell responses were induced in 71% of the mosaic vaccine recipients versus 48% of the CON-S recipients and 48% of the natural Env recipients. The mean number of T cell epitopes recognized was 2.5 (95% CI, 1.2-4.2) for mosaic recipients, 1.6 (95% CI, 0.82-2.6) for CON-S recipients, and 1.1 (95% CI, 0.62-1.71) for Nat-B recipients. Mean breadth was significantly greater in the mosaic group than in the Nat-B group using overall (P = 0.014), prime-matched (P = 0.002), heterologous (P = 0.046), and boost-matched (P = 0.009) measures. Overall T cell breadth was largely due to Env-specific [CD4.sup.+] T cell responses. CONCLUSION. Priming with a mosaic antigen significantly increased the number of epitopes recognized by Env-specific T cells and enabled more, albeit still limited, cross-recognition of heterologous variants. Mosaic and consensus immunogens are promising approaches to address global diversity of HIV-1. TRIAL REGISTRATION. ClinicalTrials.gov NCT02296541. FUNDING. US NIH grants UM1 AI068614, UM1 AI068635, UM1 AI068618, UM1 AI069412, UL1 RR025758, P30 AI064518, UM1 AI100645, and UM1 AI144371, and Bill & Melinda Gates Foundation grant OPP52282., Introduction The tremendous global genetic diversity of HIV-1 poses a formidable challenge in the development of a globally effective HIV-1 vaccine (1, 2). Several vaccine concepts have completed efficacy trials [...]
- Published
- 2023
- Full Text
- View/download PDF
36. Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers
- Author
-
Buranapraditkun, Supranee, Pissani, Franco, Teigler, Jeffrey E, Schultz, Bruce T, Alter, Galit, Marovich, Mary, Robb, Merlin L, Eller, Michael A, Martin, Jeff, Deeks, Steven, Michael, Nelson L, and Streeck, Hendrik
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Vaccine Related (AIDS) ,Vaccine Related ,Sexually Transmitted Infections ,Immunization ,Infectious Diseases ,Prevention ,HIV/AIDS ,Health Disparities ,Clinical Research ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Infection ,Good Health and Well Being ,Adult ,B-Lymphocytes ,CD4-Positive T-Lymphocytes ,Female ,Germinal Center ,HIV Envelope Protein gp120 ,HIV Infections ,HIV Long-Term Survivors ,Humans ,Immunophenotyping ,Interleukins ,Male ,Middle Aged ,Receptors ,CXCR5 ,T-Lymphocytes ,Helper-Inducer ,B cell memory ,CD4 T cells ,IL-21 ,Tfh cells ,elite controllers ,human immunodeficiency virus ,Biological Sciences ,Agricultural and Veterinary Sciences ,Medical and Health Sciences ,Virology ,Agricultural ,veterinary and food sciences ,Biological sciences ,Biomedical and clinical sciences - Abstract
The maturation process of high-affinity antibodies is a result of intricate interactions between B cells and follicular helper T (Tfh) cells occurring in lymphoid germinal centers. HIV infection induces significant chronic immune activation, phenotypic skewing, and inflammation driven by years of continuous viral replication. High levels of viremia as well as immune activation and dysfunction have been demonstrated to have a perturbing impact on the B cell memory compartment and contribute to B cell exhaustion. Counterintuitively, the factors associated with perturbation of the B cell compartment seem to be favorable for the generation of highly affinity-matured Env-specific antibodies in a minority of HIV-infected individuals. Thus, the impact of HIV antigenemia on B cells and Tfh cell interactions warrants further exploration. We therefore studied immunophenotypes of HIV-specific B cells in individuals with differing levels of viral control using HIV Env gp120 probes and characterized the functionality of matched T cells in peripheral blood. While CXCR5+ CD4+ T cells were significantly diminished in HIV progressors, we found that a small subset of gp120-specific interleukin-21 (IL-21)-secreting CXCR5+ CD4+ T cells were significantly associated with gp120-specific B cell frequencies. In contrast, neither bulk CXCR5+ CD4+ T cells nor other HIV antigen specificities were associated with gp120-specific B cell levels. HIV-specific B cells derived from elite controllers displayed greater amounts of gp120-specific B cells in the resting memory subset, whereas HIV-specific B cells in progressors accumulated in tissue-like and activated memory subsets. Furthermore, CXCR5+ CD4+ T cells from elite controllers showed a stronger ex vivo capacity to induce B cell maturation and immunoglobulin class switching than cells from HIV progressors.IMPORTANCE Dissecting the factors that are involved in B cell maturation and antibody development is important for HIV vaccine design. In this study, we found that HIV Env-specific CXCR5+ CD4+ T cells that secrete interleukin-21 are strongly associated with B cell memory phenotypes and function. Moreover, we found that the immune responses of HIV controllers showed intrinsically better helper activity than those of HIV progressors.
- Published
- 2017
37. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response
- Author
-
Knox, James J, Buggert, Marcus, Kardava, Lela, Seaton, Kelly E, Eller, Michael A, Canaday, David H, Robb, Merlin L, Ostrowski, Mario A, Deeks, Steven G, Slifka, Mark K, Tomaras, Georgia D, Moir, Susan, Moody, M Anthony, and Betts, Michael R
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Immunology ,Prevention ,HIV/AIDS ,Infectious Diseases ,Immunization ,Emerging Infectious Diseases ,Sexually Transmitted Infections ,Vaccine Related (AIDS) ,Vaccine Related ,2.1 Biological and endogenous factors ,2.2 Factors relating to the physical environment ,Aetiology ,Infection ,Good Health and Well Being ,AIDS/HIV ,Biomedical and clinical sciences ,Health sciences - Abstract
Humoral immunity is critical for viral control, but the identity and mechanisms regulating human antiviral B cells are unclear. Here, we characterized human B cells expressing T-bet and analyzed their dynamics during viral infections. T-bet+ B cells demonstrated an activated phenotype, a distinct transcriptional profile, and were enriched for expression of the antiviral immunoglobulin isotypes IgG1 and IgG3. T-bet+ B cells expanded following yellow fever virus and vaccinia virus vaccinations and also during early acute HIV infection. Viremic HIV-infected individuals maintained a large T-bet+ B cell population during chronic infection that was associated with increased serum and cell-associated IgG1 and IgG3 expression. The HIV gp140-specific B cell response was dominated by T-bet-expressing memory B cells, and we observed a concomitant biasing of gp140-specific serum immunoglobulin to the IgG1 isotype. These findings suggest that T-bet induction promotes antiviral immunoglobulin isotype switching and development of a distinct T-bet+ B cell subset that is maintained by viremia and coordinates the HIV Env-specific humoral response.
- Published
- 2017
38. Multi-omics analyses reveal that HIV-1 alters CD4+ T cell immunometabolism to fuel virus replication
- Author
-
Guo, Haitao, Wang, Qi, Ghneim, Khader, Wang, Li, Rampanelli, Elena, Holley-Guthrie, Elizabeth, Cheng, Liang, Garrido, Carolina, Margolis, David M., Eller, Leigh A., Robb, Merlin L., Sekaly, Rafick-Pierre, Chen, Xian, Su, Lishan, and Ting, Jenny P.-Y.
- Published
- 2021
- Full Text
- View/download PDF
39. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
- Author
-
Ake, Julie A., Buchbinder, Susan, Buleza, Karen, Cohen, Kristen W., Crowell, Trevor A., Euler, Zelda, Frank, Ian, Goedhart, Dimitri, Keefer, Michael, Kelly, Colleen, Mayer, Ken, Nkolola, Joseph, Peter, Lauren, Robb, Merlin L., Rouphael, Nadine, Scheppler, Lorenz, Sobieszczyk, Magda, Van Tieu, Hong, Baden, Lindsey R, Stieh, Daniel J, Sarnecki, Michal, Walsh, Stephen R, Tomaras, Georgia D, Kublin, James G, McElrath, M Juliana, Alter, Galit, Ferrari, Guido, Montefiori, David, Mann, Philipp, Nijs, Steven, Callewaert, Katleen, Goepfert, Paul, Edupuganti, Srilatha, Karita, Etienne, Langedijk, Johannes P, Wegmann, Frank, Corey, Lawrence, Pau, Maria G, Barouch, Dan H, Schuitemaker, Hanneke, and Tomaka, Frank
- Published
- 2020
- Full Text
- View/download PDF
40. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
- Author
-
Ake, Julie A., Paolino, Kristopher, Hutter, Jack N., Cicatelli, Susan Biggs, Eller, Leigh Anne, Eller, Michael A., Costanzo, Margaret C., Paquin-Proulx, Dominic, Robb, Merlin L., Tran, Chi L., Anova, Lalaine, Jagodzinski, Linda L., Ward, Lucy A., Kilgore, Nicole, Rusnak, Janice, Bounds, Callie, Badorrek, Christopher S., Hooper, Jay W., Kwilas, Steven A., and Ilsbroux, Ine
- Subjects
HIV ,IMMUNE response ,CLINICAL trials ,EBOLA virus ,VACCINATION - Abstract
The safety and immunogenicity of the two-dose Ebola vaccine regimen MVA-BN-Filo, Ad26.ZEBOV, 14 days apart, was evaluated in people without HIV (PWOH) and living with HIV (PLWH). In this observer-blind, placebo-controlled, phase 2 trial, healthy adults were randomized (4:1) to receive MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), or two doses of saline/placebo, administered intramuscularly 14 days apart. The primary endpoints were safety (adverse events (AEs)) and immunogenicity (Ebola virus (EBOV) glycoprotein-specific binding antibody responses). Among 75 participants (n = 50 PWOH; n = 25 PLWH), 37% were female, the mean age was 44 years, and 56% were Black/African American. AEs were generally mild/moderate, with no vaccine-related serious AEs. At 21 days post-dose 2, EBOV glycoprotein-specific binding antibody responder rates were 100% among PWOH and 95% among PLWH; geometric mean antibody concentrations were 6286 EU/mL (n = 36) and 2005 EU/mL (n = 19), respectively. A total of 45 neutralizing and other functional antibody responses were frequently observed. Ebola-specific CD4+ and CD8+ T-cell responses were polyfunctional and durable to at least 12 months post-dose 2. The regimen was well tolerated and generated robust, durable immune responses in PWOH and PLWH. Findings support continued evaluation of accelerated vaccine schedules for rapid deployment in populations at immediate risk. Trial registration: NCT02598388 (submitted 14 November 2015). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
- Author
-
Pitisuthitham, Arom, Sabmee, Yupa, Sirisopana, Narongrid, Eamsila, Chirapa, Savaraj, Prapaporn, Labwech, Wanlaya, Teerachia, Siriluck, Chotirosniramit, Nuntisa, Supindham, Taweewat, Pruenglampoo, Boonlure, Sugandhavesa, Patcharaphan, Kosashunhanan, Natthapol, Kaewthip, Oranitcha, Sroysuwan, Piyathida, Jarujareet, Pawinee, Ratto-Kim, Silvia, Molnar, Sebastian, Schoen, Jesse, Churikanont, Nampueng, Getchalarat, Saowanit, Sangnoi, Nongluck, Nuntapinit, Bessara, Phramtong, Anant, Grandin, Pornsuk V., Madnote, Sirinan, Rittiroongrad, Surawach, Kaewboon, Boot, Trichavaroj, Rapee, Puangkaew, Jiraporn, Chantakulkij, Somsak, Rakyat, Phiromrat, Panjapornsuk, Pornchanok, Tragonlugsana, Nipattra, Chuenarom, Weerawan, de Souza, Mark, Ngauy, Viseth, Phanuphak, Nittaya, Chomchey, Nitiya, Saengtawan, Puttachard, Teeratakulpisarn, Nipat, Rerknimitr, Rungsun, Kroon, Eugene, Lee, Carter A., Chinaworapong, Suchada, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Chariyalertsak, Suwat, Kaewkungwal, Jaranit, Dawson, Peter, Dhitavat, Jittima, Phonrat, Benjaluck, Akapirat, Siriwat, Karasavvas, Nicos, Wieczorek, Lindsay, Polonis, Victoria, Eller, Michael A, Pegu, Poonam, Kim, Dohoon, Schuetz, Alexandra, Jongrakthaitae, Surat, Zhou, Yingjun, Sinangil, Faruk, Phogat, Sanjay, Diazgranados, Carlos A, Tartaglia, James, Heger, Elizabeth, Smith, Kirsten, Michael, Nelson L, Excler, Jean-Louis, Robb, Merlin L, Kim, Jerome H, O'Connell, Robert J, and Vasan, Sandhya
- Published
- 2020
- Full Text
- View/download PDF
42. Retention of a cohort of men who have sex with men and transgender women at risk for and living with HIV in Abuja and Lagos, Nigeria: a longitudinal analysis
- Author
-
Kayode, Blessing O., Mitchell, Andrew, Ndembi, Nicaise, Kokogho, Afoke, Ramadhani, Habib O., Adebajo, Sylvia, Robb, Merlin L., Baral, Stefan D., Ake, Julie A., Charurat, Manhattan E., Crowell, Trevor A., and Nowak, Rebecca G.
- Subjects
Transgender people -- Health aspects ,HIV infections -- Care and treatment ,MSM (Men who have sex with men) -- Health aspects ,Patient compliance -- Evaluation ,Health behavior -- Evaluation ,Health - Abstract
Introduction: Men who have sex with men (MSM), and transgender women (TGW), face specific obstacles to retention in care, particularly in settings with stigmatization such as sub-Saharan Africa. We evaluated the impacts of HIV status and other factors on loss-to-follow-up (LTFU) and visit adherence among MSM and TGW in Abuja and Lagos, Nigeria. Methods: TRUST/RV368 is an open cohort that provides comprehensive and integrated prevention and treatment services for HIV and sexually transmitted infections (STIs) at community venues supportive of sexual and gender minorities. Recruitment began in March 2013 and participants were followed every three months for up to 18 months. LTFU was defined as not presenting for an expected visit in the past 180 days. Visit adherence was calculated as a rate of completed visits adjusted by the number of three-month intervals elapsed since enrolment. HIV and other factors predictive of LTFU and visit adherence were evaluated using Cox proportional hazards and Poisson regression models, respectively. Results: A total of 1447 participants who completed enrolment evaluations over two visits as of November 2018 were included in these analyses. Their median age was 24 years (interquartile range [IQR]: 21 to 28) and 53% (n = 766) were living with HIV. LTFU occurred in 56% (n = 808) and visit adherence was 0.62 (95% confidence interval: 0.61 to 0.64) visits per three-month interval. Participants at risk and living with HIV had median follow-up times of 12 months (IQR: 6 to 22), and 21 months (IQR: 12 to 30), respectively (p < 0.01). After controlling for other factors, LTFU was less common among participants living with HIV or other STIs and more common among those who did not own a cell phone, sold sex and had never undergone HIV testing prior to enrolment. These factors had parallel associations with visit adherence. Conclusions: Retention was suboptimal in Nigerian clinics designed to serve MSM and TGW. Particularly high LTFU and low visit adherence among participants at risk for HIV could complicate deployment of HIV prevention interventions. Marketing the benefits of testing, improving access to cell phones and nurturing more trust with clients may improve retention among marginalized communities in Nigeria. Keywords: sub-Saharan Africa; retention in care; treatment adherence and compliance; sexual and gender minorities; HIV, 1 | INTRODUCTION Retention of people at risk for and living with HIV (PLWH) in evidence-based programmes has its challenges in countries across sub-Saharan Africa where loss to follow-up (LTFU) [...]
- Published
- 2020
- Full Text
- View/download PDF
43. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
- Author
-
Dayan, Gustavo H, primary, Rouphael, Nadine, additional, Walsh, Stephen R, additional, Chen, Aiying, additional, Grunenberg, Nicole, additional, Allen, Mary, additional, Antony, Johannes, additional, Asante, Kwaku Poku, additional, Bhate, Amit Suresh, additional, Beresnev, Tatiana, additional, Bonaparte, Matthew I, additional, Celle, Médéric, additional, Ceregido, Maria Angeles, additional, Corey, Lawrence, additional, Dobrianskyi, Dmytro, additional, Fu, Bo, additional, Grillet, Marie-Helene, additional, Keshtkar-Jahromi, Maryam, additional, Juraska, Michal, additional, Kee, Jia Jin, additional, Kibuuka, Hannah, additional, Koutsoukos, Marguerite, additional, Masotti, Roger, additional, Michael, Nelson L, additional, Neuzil, Kathleen M, additional, Reynales, Humberto, additional, Robb, Merlin L, additional, Villagómez Martínez, Sandra M, additional, Sawe, Fredrick, additional, Schuerman, Lode, additional, Tong, Tina, additional, Treanor, John, additional, Wartel, T Anh, additional, Diazgranados, Carlos A, additional, Chicz, Roman M, additional, Gurunathan, Sanjay, additional, Savarino, Stephen, additional, Sridhar, Saranya, additional, Abalos, Karina, additional, Accini, Jose, additional, Aloysia, Naveena, additional, Amuasi, John Humphrey, additional, Ansah, Nana Akosua, additional, Benkeser, David, additional, Berge, Aude, additional, Beyko, Hanna, additional, Bilotkach, Oleksandra, additional, Breuer, Thomas, additional, Bonfanti, Alberto Cadena, additional, Bukusi, Elisabeth, additional, Canter, Richard, additional, Carrillo, Jaime Augusto, additional, Chansinghakul, Danaya, additional, Coux, Florence, additional, Das, Chandan, additional, Das, Santa Kumar, additional, Devlin, Louis, additional, Espinoza, Luis, additional, Fay, Michael, additional, Follmann, Dean, additional, Frago, Carina, additional, Garinga, Agnes, additional, Gilbert, Peter B, additional, Gonzalez, Claudia, additional, Granados, Maria Angelica, additional, Guillery, Lea, additional, Huang, Ying, additional, Hudzina, Kathy, additional, Jain, Manish, additional, Kanodia, Piush, additional, Khandelwal, Nitin, additional, Mutuluuza, Cissy Kityo, additional, Kiweewa, Francis, additional, Kiwanuka, Noah, additional, Kosolsak, Chalit, additional, Kukian, Darshna, additional, Kushwaha, Jitendra Singh, additional, Laot, Thelma, additional, Lopez-Medina, Eduardo, additional, Macareno Arroyo, Hugo, additional, Mandaliya, Kishorchandra, additional, Mamod, Stephanie, additional, Mangarule, Somnath, additional, Martínez, Javier, additional, McClelland, Scott, additional, Menard, Lisa, additional, Mendoza, Sandra, additional, Mohapatra, Satyajit, additional, Moreau, Catherine, additional, Mugo, Nelly, additional, Nduba, Videlis, additional, Noriega, Fernando, additional, Ntege, Patricia Nahirya, additional, Okech, Brenda, additional, Otero, Maria, additional, Ouma, Samuel Gurrion, additional, Oyieko, Janet, additional, Paredes, Mercedes, additional, Pardo, Erwin, additional, Postol, Svitlana, additional, Pekala, David, additional, Peng, Penny, additional, Py, Marie-Laure, additional, Rivas, Enrique, additional, Rivero, Rafael, additional, Rodriguez, Edith, additional, Saleh, Mansoor, additional, Sánchez, Pedro, additional, Sater, Nessryne, additional, Shah, Jinen, additional, Shrestha, Rajeev, additional, Siika, Abraham, additional, Singh, Chandramani, additional, Singh, Veer Bahadur, additional, Tamrakar, Dipesh, additional, Tavares Da-Silva, Fernanda, additional, Otieno Tina, Lucas, additional, Velasquez, Hector, additional, Wabwire, Deo, additional, Wajja, Anne, additional, Zaworski, Elodie, additional, and Zhang, Nianxian, additional
- Published
- 2023
- Full Text
- View/download PDF
44. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
- Author
-
Dayan, Gustavo H., primary, Rouphael, Nadine, additional, Walsh, Stephen R., additional, Chen, Aiying, additional, Grunenberg, Nicole, additional, Allen, Mary, additional, Antony, Johannes, additional, Bhate, Amit Suresh, additional, Beresnev, Tatiana, additional, Bonaparte, Matthew I., additional, Celle, Médéric, additional, Ceregido, Maria Angeles, additional, Corey, Lawrence, additional, Fu, Bo, additional, Grillet, Marie-Helene, additional, Keshtkar-Jahromi, Maryam, additional, Juraska, Michal, additional, Kee, Jia Jin, additional, Kaali, Seyram, additional, Koutsoukos, Marguerite, additional, Masotti, Roger, additional, Michael, Nelson L., additional, Neuzil, Kathleen M., additional, Reynales, Humberto, additional, Robb, Merlin L., additional, Uchiyama, Akiyoshi, additional, Sawe, Fredrick, additional, Schuerman, Lode, additional, Shrestha, Rajeev, additional, Tong, Tina, additional, Treanor, John, additional, Diazgranados, Carlos A., additional, Chicz, Roman M., additional, Gurunathan, Sanjay, additional, Savarino, Stephen, additional, Sridhar, Saranya, additional, Abalos, Karina, additional, Adams, Michael, additional, Allaw, Mohamed, additional, Aloysia, Naveena, additional, Amuasi, John Humphrey, additional, Ansah, Nana Akosua, additional, Asante, Kwaku Poku, additional, Benkeser, David, additional, Berge, Aude, additional, Breuer, Thomas, additional, Briesemeister, Liz, additional, Broder, Gail, additional, Bonfanti, Alberto Cadena, additional, Calinescu, Cornell, additional, Canter, Richard, additional, Carrillo, Jaime Augusto, additional, Chansinghakul, Danaya, additional, Coux, Florence, additional, Das, Chandan, additional, Davies, Matthew, additional, Devlin, Louis, additional, Fay, Michael, additional, Follmann, Dean, additional, Frago, Carina, additional, Fukase, Hiroyuki, additional, Garinga, Agnes, additional, Gilbert, Peter B., additional, Gonzalez, Claudia, additional, Granados, Maria Angelica, additional, Greiwe, Cathy, additional, Guillery, Lea, additional, Hall, Jessicalee, additional, Henderson, Jeffrey, additional, Huang, Ying, additional, Hudzina, Kathy, additional, Hural, John, additional, Hutchens, Mark, additional, Jain, Manish, additional, Jennings, William, additional, Kanodia, Piush, additional, Kimmel, Murray, additional, Kirby, William, additional, Khandelwal, Nitin, additional, Kopp, James, additional, Kosolsak, Chalit, additional, Kublin, Jim, additional, Kukian, Darshna, additional, Kushwaha, Jitendra Singh, additional, Laot, Thelma, additional, Lopez-Medina, Eduardo, additional, Arroyo, Hugo Macareno, additional, Mamod, Stephanie, additional, Mangarule, Somnath, additional, Martin, Troy, additional, Menard, Lisa, additional, Mendoza, Sandra, additional, Meyer, Robert, additional, Middleton, Randle, additional, Miracle, Jill, additional, Mizuyama, Kazuyuki, additional, Mohapatra, Satyajit, additional, Moreau, Catherine, additional, Murray, Linda, additional, Nagamatsu, Shinya, additional, Newberg, Joseph, additional, Noriega, Fernando, additional, Nugent, Paul, additional, Peake-Andrasik, Michele, additional, Pekala, David, additional, Peng, Penny, additional, Py, Marie-Laure, additional, Ramirez, Shelly, additional, Reddy, Chinthaparthi Prabhakar, additional, Reynolds, Michelle, additional, Rivas, Enrique, additional, Sater, Nessryne, additional, Shah, Jinen, additional, Sher, Lawrence, additional, Sieger, Silva, additional, Singh, Chandramani, additional, Singh, Veer Bahadur, additional, Sirisuphmitr, Nuchra, additional, Starkey, Thomas, additional, Suzuki, Kazuo, additional, Tamrakar, Dipesh, additional, Tangemen, Cayce, additional, Da-Silva, Fernanda Tavares, additional, Taylor, David, additional, Tharenos, Leslie, additional, Wartel, T. Anh, additional, Zaworski, Elodie, additional, and Zhang, Nianxian, additional
- Published
- 2023
- Full Text
- View/download PDF
45. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
- Author
-
Sobieszczyk, Magdalena E., Maaske, Jill, Falsey, Ann R., Sproule, Stephanie, Robb, Merlin L., Frenck, Robert W., Jr., Tieu, Hong-Van, Mayer, Kenneth H., Corey, Lawrence, Neuzil, Kathleen M., Tong, Tina, Isaacs, Margaret Brewinski, Janes, Holly, Bansal, Himanshu, Edwards, Lindsay M., Green, Justin A., Kelly, Elizabeth J., Shoemaker, Kathryn, Takas, Therese, White, Tom, Bhuyan, Prakash, Villafana, Tonya, and Hirsch, Ian
- Subjects
Communicable diseases in children -- Prevention ,Pediatric research ,Health care industry ,AZD1222 (Vaccine) -- Testing - Abstract
BACKGROUND. We report updated safety, efficacy, and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) from an ongoing phase 3 trial. METHODS. Adults at increased risk of SARS-CoV-2 infection were randomized (2:1), stratified by age, to receive 2 doses of AZD1222 or placebo. The primary efficacy end point was confirmed SARS-CoV-2 reverse-transcriptase PCR-positive (RT-PCRpositive) symptomatic COVID-19 at 15 or more days after a second dose in baseline SARS-CoV-2-seronegative participants. The 21,634 and 10,816 participants were randomized to AZD1222 and placebo, respectively. FINDINGS. Data cutoff for this analysis was July 30, 2021; median follow-up from second dose was 78 and 71 days for the doubleblind period (censoring at unblinding or nonstudy COVID-19 vaccination) and 201 and 82 days for the period to nonstudy COVID-19 vaccination (regardless of unblinding) in the AZD1222 and placebo groups, respectively. For the primary efficacy end point in the double-blind period (141 and 184 events; incidence rates: 39.2 and 118.8 per 1,000 person years), vaccine efficacy was 67.0% (P < 0.001). In the period to nonstudy COVID-19 vaccination, incidence of events remained consistently low and stable through 6 months in the AZD1222 group; for the primary efficacy end point (328 and 219 events; incidence rates: 36.4, 108.4) and severe/ critical disease (5 and 13 events; incidence rates: 0.6, 6.4), respective vaccine efficacy estimates were 65.1% and 92.1%. AZD1222 elicited humoral immune responses over time, with waning at day 180. No emergent safety issues were seen. CONCLUSION. AZD1222 is safe and well tolerated, demonstrating durable protection and immunogenicity with median followup (AZD1222 group) of 6 months. TRIAL REGISTRATION. ClinicalTrials.gov NCT04516746. FUNDING. AstraZeneca; US government., Introduction There is an ongoing critical need for vaccination in the fight against the global COVID-19 pandemic. Understanding the durability of vaccine efficacy (VE) and immunogenicity is important in the [...]
- Published
- 2022
- Full Text
- View/download PDF
46. Associations of gender identity with sexual behaviours, social stigma and sexually transmitted infections among adults who have sex with men in Abuja and Lagos, Nigeria
- Author
-
Leevan, Elyse, Hu, Fengming, Mitchell, Andrew B., Kokogho, Afoke, Adebajo, Sylvia, Garges, Eric C., Qian, Haoyu, Ake, Julie A., Robb, Merlin L., Charurat, Manhattan E., Baral, Stefan D., Nowak, Rebecca G., and Crowell, Trevor A.
- Subjects
Sexually transmitted diseases -- Risk factors -- Distribution ,Sex -- Analysis ,Disease transmission -- Analysis ,Gender identity -- Analysis ,Stigma (Social psychology) -- Analysis ,Company distribution practices ,Health - Abstract
: Introduction: Sexual and gender minority populations are disproportionately affected by the global syndemic of HIV and other sexually transmitted infections (STIs). We hypothesized that transgender women (TGW) and non‐binary individuals in Nigeria have more STIs than cis‐gender men who have sex with men (cis‐MSM), and that experiences of stigma and sexual practices differ between these three groups. Methods: From 2013 to 2020, TRUST/RV368 enrolled adults assigned male sex at birth who reported anal sex with men in Abuja and Lagos, Nigeria. Participants were tested for STIs and completed questionnaires about sexual behaviours and social stigma every 3 months. Participants were categorized as cis‐MSM, TGW or non‐binary/other based on self‐reported gender identity. Gender group comparisons were made of HIV, gonorrhoea and chlamydia prevalence and incidence; stigma indicators; and condom use during anal sex. Results: Among 2795 participants, there were 2260 (80.8%) cis‐MSM, 284 (10.2%) TGW and 251 (9.0%) non‐binary/other individuals with median age of 23 years (interquartile range 20–27). HIV prevalence among cis‐MSM, TGW and non‐binary/other participants was 40.8%, 51.5% and 47.6%, respectively (p = 0.002). HIV incidence was 8.7 cases per 100 person‐years (PY) (95% confidence interval [CI] 6.9–10.8), 13.1 cases/100 PY (95% CI 6.5–23.4) and 17.6 cases/100 PY (95% CI 9.8–29.0, p = 0.025), respectively. Anorectal gonorrhoea incidence was lower in cis‐MSM than TGW (22.2 [95% CI 19.6–25.0] vs. 35.9 [95% CI 27.3–46.3]). TGW were more likely than cis‐MSM to report being affected by stigma, including assault (47.2% vs. 32.3%), fear of walking around (32.4% vs. 19.2%) and healthcare avoidance (25.0% vs. 19.1%; all p < 0.05). TGW were more likely to report always using condoms than non‐binary/other individuals (35.3% vs. 26.2%, p = 0.041) during receptive anal sex. Conclusions: Sexual and gender minorities in Nigeria have heterogeneous sexual behaviours and experiences of social stigma that may influence the vulnerability to HIV and other STIs. There is a need for tailored interventions that acknowledge and are informed by gender. Further research is needed, particularly among understudied non‐binary individuals, to better understand disparities and inform tailored interventions to improve outcomes among these communities., INTRODUCTION At least 25% of the global burden of HIV is borne by individuals who are sexual or gender minorities, which include individuals who identify as lesbian, gay, bisexual, asexual, [...]
- Published
- 2022
- Full Text
- View/download PDF
47. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
- Author
-
Pantaleo, Giuseppe, Janes, Holly, Karuna, Shelly, Grant, Shannon, Ouedraogo, G Laissa, Allen, Mary, Tomaras, Georgia D, Frahm, Nicole, Montefiori, David C, Ferrari, Guido, Ding, Song, Lee, Carter, Robb, Merlin L, Esteban, Mariano, Wagner, Ralf, Bart, Pierre-Alexandre, Rettby, Nils, McElrath, M Juliana, Gilbert, Peter B, Kublin, James G, and Corey, Lawrence
- Published
- 2019
- Full Text
- View/download PDF
48. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
- Author
-
Cale, Evan M., Bai, Hongjun, Bose, Meera, Messina, Michael A., Colby, Donn J., Sanders-Buell, Eric, Dearlove, Bethany, Li, Yifan, Engeman, Emily, Silas, Daniel, O'Sullivan, Anne Marie, Mann, Brendan, Pinyakorn, Suteeraporn, Intasan, Jintana, Benjapornpong, Khunthalee, Sacdalan, Carlo, Kroon, Eugene, Phanuphak, Nittaya, Gramzinski, Robert, Vasan, Sandhya, Robb, Merlin L., Michael, Nelson L., Lynch, Rebecca M., Bailer, Robert T., Pagliuzza, Amelie, Chomont, Nicolas, Pegu, Amarendra, Doria-Rose, Nicole A., Trautmann, Lydie, Crowell, Trevor A., Mascola, John R., Ananworanich, Jintanat, Tovanabutra, Sodsai, and Rolland, Morgane
- Subjects
Highly active antiretroviral therapy -- Health aspects ,HIV -- Genetic aspects -- Prevention ,Antiretroviral agents -- Health aspects ,Antibodies -- Genetic aspects -- Health aspects ,Antigenic determinants -- Genetic aspects -- Health aspects ,Health care industry - Abstract
Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed individuals. Viral rebound occurred in all individuals, yet VRC01 infusions modestly delayed rebound and participants who showed a faster decay of VRC01 in serum rebounded more rapidly. Participants with strains most sensitive to VRC01 or with VRC01 epitope motifs similar to known VRC01- susceptible strains rebounded later. Upon rebound, HIV-1 sequences were indistinguishable from those sampled at diagnosis. Across the cohort, participant-derived Env showed different sensitivity to VRC01 neutralization (including 2 resistant viruses), yet neutralization sensitivity was similar at diagnosis and after rebound, indicating the lack of selection for VRC01 resistance during treatment interruption. Our results showed that viremia rebounded despite the absence of HIV-1 adaptation to VRC01 and an average VRC01 trough of 221 micro]g/mL. Although VRC01 levels were insufficient to prevent a resurgent infection, knowledge that they did not mediate Env mutations in acute-like viruses is relevant for antibody-based strategies in acute infection., Introduction Analytic treatment interruption (ATI) studies can help evaluate strategies to mediate long-term remission in HIV-1-infected persons. An ATI study tested the impact of the administration of the broadly neutralizing [...]
- Published
- 2020
- Full Text
- View/download PDF
49. Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption
- Author
-
Mitchell, Julie L., Takata, Hiroshi, Muir, Roshell, Colby, Donn J., Kroon, Eugene, Crowell, Trevor A., Sacdalan, Carlo, Pinyakorn, Suteeraporn, Puttamaswin, Suwanna, Benjapornpong, Khunthalee, Trichavaroj, Rapee, Tressler, Randall L., Fox, Lawrence, Polonis, Victoria R., Bolton, Diane L., Maldarelli, Frank, Lewin, Sharon R., Haddad, Elias K., Phanuphak, Praphan, Robb, Merlin L., Michael, Nelson L., de Souza, Mark, Phanuphak, Nittaya, Ananworanich, Jintanat, and Trautmann, Lydie
- Subjects
Thermo Fisher Scientific Inc. ,Highly active antiretroviral therapy -- Health aspects ,Vorinostat -- Health aspects ,Viremia -- Health aspects ,HIV tests -- Health aspects ,HIV -- Health aspects ,Infection -- Health aspects ,Dendritic cells -- Health aspects ,Maraviroc -- Health aspects ,Virus replication -- Health aspects ,Scientific equipment industry -- Health aspects ,Health care industry - Abstract
Plasmacytoid dendritic cells (pDCs) are robust producers of IFN[alpha] and one of the first immune cells to respond to SIV infection. To elucidate responses to early HIV-1 replication, we studied blood pDCs in 29 HIV-infected participants who initiated antiretroviral therapy during acute infection and underwent analytic treatment interruption (ATI). We observed an increased frequency of partially activated pDCs in the blood before detection of HIV RNA. Concurrent with peak pDC frequency, we detected a transient decline in the ability of pDCs to produce IFN[alpha] in vitro, which correlated with decreased phosphorylation of IFN regulatory factory 7 (IRF7) and NF-[kappa]B. The levels of phosphorylated IRF7 and NF-[kappa]B inversely correlated with plasma IFNA2 levels, implying that pDCs were refractory to in vitro stimulation after IFN[alpha] production in vivo. After ATI, decreased expression of IFN genes in pDCs inversely correlated with the time to viral detection, suggesting that pDC IFN loss is part of an effective early immune response. These data from a limited cohort provide a critical first step in understanding the earliest immune response to HIV-1 and suggest that changes in blood pDC frequency and function can be used as an indicator of viral replication before detectable plasma viremia., Introduction Plasmacytoid dendritic cells (pDCs) are important mediators of the early innate immune response to viral infection through robust production of type I IFNs, particularly IFN[alpha] (1, 2). pDCs recognize [...]
- Published
- 2020
- Full Text
- View/download PDF
50. Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinic-based observational cohort study in four African countries
- Author
-
Esber, Allahna L., Coakley, Peter, Ake, Julie A., Bahemana, Emmanuel, Adamu, Yakubu, Kiweewa, Francis, Maswai, Jonah, Owuoth, John, Robb, Merlin L., Polyak, Christina S., and Crowe, Trevor A.
- Subjects
Walter Reed Army Institute of Research ,Highly active antiretroviral therapy ,HIV ,Antiretroviral agents ,Health ,World Health Organization - Abstract
Introduction: World Health Organization (WHO) guidelines have shifted over time to recommend earlier initiation of antiretroviral therapy (ART) and now encourage ART initiation on the day of HIV diagnosis, if possible. However, barriers to ART access may delay initiation in resource-limited settings. We characterized temporal trends and other factors influencing the interval between HIV diagnosis and ART initiation among participants enrolled in a clinic-based cohort across four African countries. Methods: The African Cohort Study enrols adults engaged in care at 12 sites in Uganda, Kenya, Tanzania and Nigeria. Participants provide a medical history, complete a physical examination and undergo laboratory assessments every six months. Participants with recorded dates of HIV diagnosis were categorized by WHO guideline era ( Results and discussion: From January 2013 to September 2019, a total of 2888 adults living with HIV enrolled with known diagnosis dates. Median time to ART initiation decreased from 22.0 months (interquartile range (IQR) 4.0 to 77.3) among participants diagnosed prior to 2006 to 0.5 months (IQR 0.2 to 1.8) among those diagnosed in 2016 and later. Comparing those same periods, CD4 nadir increased from a median of 166 cells/[mm.sup.3] (IQR: 81 to 286) to 298 cells/[mm.sup.3] (IQR: 151 to 501). In the final adjusted model, participants diagnosed in each subsequent WHO guideline era had increased rates of ART initiation compared to those diagnosed before 2006. CD4 nadir >500 cells/[mm.sup.3] was independently associated with a lower rate of ART initiation as compared to CD4 nadir 50 years at diagnosis was independently associated with shorter time to ART initiation as compared to 18 to 29 years (HR: 1.38; 95% CI: 1.19 to 1.61). Conclusions: Consistent with changing guidelines, the interval between diagnosis and ART initiation has decreased over time. Still, many adults living with HIV initiated treatment with low CD4, highlighting the need to diagnose HIV earlier while improving access to immediate ART after diagnosis. Keywords: antiretroviral therapy; highly active; HIV-1; treatment initiation; Africa; time-to-treatment; CD4 lymphocyte count, (1) | INTRODUCTION The introduction of antiretroviral therapy (ART) proved a turning point in the fight against HIV, leading to dramatic decreases in HIV-related morbidity and mortality [1,2]. However, the [...]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.